Borderline Personality Disorder
Abstract
This review summarizes the current body of knowledge about borderline personality disorder (BPD). Each section describes the development of BPD’s knowledge base in the 33 years since the diagnosis became part of the American Psychiatric Association’s standard diagnostic classification system. The changes in our understanding are remarkable with respect to virtually every consideration of BPD’s etiology, course, and treatment. This expansion of knowledge has forced the authors to have to choose what we deem is most important, and thereby this review may overlook or underrepresent other significant developments. Nonetheless, we expect readers will share our excitement about what’s been learned. Throughout our review we will highlight very interesting and distinctly different questions that now surround this diagnosis.
Definition
Ontogeny
The first efforts to define the borderline condition were by clinicians who recognized a group of patients within their office practice (1) or inpatient settings (2) that didn’t fit into existing categories but seemed like atypical variants of other disorders. Specifically, like schizophrenia, they had lapses in their reality testing; like depression, they were often desperately unhappy; and like antisocial personality, they seemed impulsive and willfully noncompliant. Three more-or-less concurrent subsequent developments brought wider attention to this condition in the late 1960s. Grinker gave the condition an academic blessing by making the first empirical effort to define the “borderline syndrome” (3). Kety et al. (4), who were conducting a twin study of schizophrenia, needed to include atypical variants to gain statistical power. In the process, they adopted the concept “borderline schizophrenia” and this gave the condition importance as a possible key to the expanded classification of “bordering”—i.e., spectrum—disorders. Finally, Kernberg (5, 6) awoke the psychoanalytic community to the “borderline personality organization” construct. His descriptive effort highlighted the identity problems, primitive defenses, and transient failures of reality testing that still aptly describe these patients. More importantly, he fueled the hope that skilled intensive psychodynamic therapies could affect major changes. Thus descriptive psychiatry, biological psychiatry, and psychotherapeutic hopes dramatically increased attention to these patients.
Borrowing from these contributions and from the diverse literature that had otherwise accumulated about these patients, the senior author proposed a definition (7), developed a reliable structured interview (8, 9), and, using these, conducted a project that established the syndrome’s discriminating features and diagnostic threshold (10). Thus the criteria were developed and formed the basis for the disorder’s entry into the official classification system in 1980 (DSM-III). Those criteria have been shown to have internal coherence with a single latent structure (11–14). With only modest revisions those criteria still endure in DSM-5 (see Table 1).
| A pervasive pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts, as indicated by five (or more) of the following: |
| (1) frantic efforts to avoid real or imagined abandonment. Note: Do not include suicidal or self-mutilating behavior covered in criterion 5. |
| (2) a pattern of unstable and intense interpersonal relationships characterized by alternating between extremes of idealization and devaluation |
| (3) identity disturbance: markedly and persistently unstable self-image or sense of self |
| (4) impulsivity in at least two areas that are potentially self-damaging (e.g., spending, sex, substance abuse, reckless driving, binge eating). Note: Do not include suicidal or self-mutilating behavior covered in criterion 5. |
| (5) recurrent suicidal behavior, gestures, or threats, or self-mutilating behavior |
| (6) affective instability due to a marked reactivity of mood (e.g., intense episodic dysphoria, irritability, or anxiety usually lasting a few hours and only rarely more than a few days) |
| (7) chronic feelings of emptiness |
| (8) inappropriate, intense anger or difficulty controlling anger (e.g., frequent displays of temper, constant anger, recurrent physical fights) |
| (9) transient, stress-related paranoid ideation or severe dissociative symptoms |
a
Reprinted from American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. Washington, DC, APA, 2013. Copyright © 2013, American Psychiatric Association. Used with permission.
Controversies
Despite the diagnosis’s relative descriptive stability since 1980, its integrity has been an almost continuous subject of much controversy. It was first considered a spectrum variant of schizophrenia (as noted above), then of MDD, then of PTSD, and then bipolar disorder. Of note, a considerable body of research has consistently validated the disorder’s internal coherence, its discriminability from other disorders and—as will be described in this review—its unique course, heritability, pathogenesis, and treatability with diagnosis-specific therapies (15). Thus, from the point of view of the usual standards, by which validity of a psychiatric disorder is established, it has met the tests. It appears in DSM-5 and as a diagnosis whose usage is now legitimate for adolescents.
The questions that currently surround the borderline diagnosis appear to supersede its established validity. Where it belongs in the classification system is one such issue. Unlike the other personality disorders it has empirically validated treatments, and, in the presence of other major psychiatric disorders its treatment often takes priority. These distinctions set it apart from other personality disorders. Moreover, within the nosological superstructure of internalizing versus externalizing dimensions it appears to occupy some space of its own, whereby it combines characteristics of both (16–18). Moreover, its genetic template overlaps with that for other personality disorders and also with the genetic template for axis I disorders (19, 20). Hence, it is even difficult to see it as a spectrum variant within the major meta-schemes of classification.
In an effort to replace all of the existing and clinically traditional categories of personality disorder with a trait dimensional scheme, the ICD-12 will remove BPD–and all other PD categories–from its classification. Within the DSM-5 personality workgroup, there was debate about its redefinition (21). That debate concerned whether BPD should be redefined as a trait disorder representing a variant of normal personality. Trying to blend personality traits with personality psychopathology, Table 2 shows the redefinition that the DSM- 5 Task Force proposed. External reviewers, including the APA Board of Trustees, judged it too radical a change, and to be insufficiently tested scientifically and clinically. It will appear in DSM-5’s Section 3 as an alternative definition in need of research.
| Typical features of borderline personality disorder are instability of self-image, personal goals, interpersonal relationships, and affects, accompanied by impulsivity, risk-taking, and/or hostility. Characteristic difficulties are apparent in identity, self-direction, empathy, and/or intimacy, as described below, along with specific maladaptive traits in the domain of Negative Affectivity, and also Antagonism and/or Disinhibition. |
| A. Moderate or greater impairment in personality functioning, manifest by characteristic difficulties in two or more of the following four areas: |
| 1. Identity: Markedly impoverished, poorly developed, or unstable self-image, often associated with excessive self-criticism; chronic feelings of emptiness; dissociative states under stress. |
| 2. Self-direction: Instability in goals, aspirations, value, or career plans. |
| 3. Empathy: Compromised ability to recognize the feelings and needs of others associated with interpersonal hypersensitivity (i.e., prone to feel slighted or insulted); perceptions of others selectively biased toward negative attributes or vulnerabilities. |
| 4. Intimacy: Intense, unstable, and conflicted close relationships, marked by mistrust, neediness, and anxious preoccupation with real or imagined abandonment; close relationships often viewed in extremes of idealization and devaluation and alternating between over-involvement and withdrawal. |
| B. Four or more of the following seven pathological personality traits, at least one which must be #5 Impulsivity, #6 Risk taking, or #7 Hostility): |
| 1. Emotional lability (an aspect of Negative Affectivity): Unstable emotional experiences and frequent mood changes; emotions that are easily aroused, intense, and/or out of proportion to events and circumstances. |
| 2. Anxiousness (an aspect of Negative Affectivity): Intense feelings of nervousness, tenseness, or panic, often in reaction to interpersonal stresses; worry about the negative effects of past unpleasant experiences and future negative possibilities; feeling fearful, apprehensive, or threatened by uncertainty; fears of falling apart or losing control. |
| 3. Separation insecurity (an aspect of Negative Affectivity): Fears of rejection by – and/or separation from – significant others, associated with fears of excessive dependency and complete loss of autonomy. |
| 4. Depressivity (an aspect of Negative Affectivity): Frequent feelings of being down, miserable, and/or hopeless; difficulty recovering from such moods; pessimism about the future; pervasive shame; feelings of inferior self-worth; thoughts of suicide and suicidal behavior. |
| 5. Impulsivity (as aspect of Disinhibition): Acting on the spur of the moment in response to immediate stimuli; acting on a momentary basis without a plan or consideration of outcomes; difficulty establishing or following plans; a sense of urgency and self-harming behavior under emotional distress. |
| 6. Risk taking (as aspect of Disinhibition): Engagement in dangerous, risky, and potentially self-damaging activities, unnecessarily and without regard to consequences; lack of concern for one’s limitations and denial of the reality of personal danger. |
| 7. Hostility (as aspect of Disinhibition): Persistent or frequent angry feelings; anger or irritability in response to minor slights and insults. |
a
Reprinted from American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. Washington, DC, APA, 2013. Copyright © 2013, American Psychiatric Association. Used with permission.
Epidemiology
Prevalence
In community samples borderline personality disorder (BPD) has a median prevalence of 1.7% (0.0%–2.7%) as estimated from all samples reviewed by Torgersen (22) and Trull et al. (23). The high prevalence rate (5.9%) found in the large epidemiologic study (24) was significantly reduced (to 2.7%) when a more conservative analysis of diagnostic data were used (23). Thus, only the latter study was used in prevalence estimation. The somewhat lower prevalence reported by some studies can be attributed to use of self-report assessments (25) or low response rate (26). BPD prevalence is comparable to prevalence of other major psychiatric disorders, such as schizophrenia or bipolar disorder, but lower than major depressive disorder or anxiety disorders (see Table 3). The lifetime prevalence of BPD is between 5.5 to 5.9% (27, 28). This disparity between cross-sectional prevalence and lifetime prevalence is consistent with the high rate of symptomatic recovery found in BPD patients (see “Natural History” and “Treatment and Outcome” subsections).
| Psychiatric disorder | Prevalence (%) |
|---|---|
| Schizophrenia | 1.1 |
| Borderline personality disorder | 1.7 |
| Bipolar I disorder | 1.3 |
| Major depressive disorder | 6.7 |
| All personality disorders | 9.1 |
| Anxiety disorders | 18.1 |
a
NIMH statistics (http://www.nimh.nih.gov/statistics/index.shtml)
Within clinical settings BPD is the most common personality disorder at different levels of care. About 6.5%–42.7% (median = 20.3%) (29) of all psychiatric inpatients and about 8%–18% (median = 11.9) (30) of all psychiatric outpatients have BPD. Frequent psychiatric hospitalizations in BPD are associated with suicidality, psychotic symptoms, and anorexia (31) but, surprisingly, not with depression. Similarly, 56% of emergency room patients admitted for suicidal behaviors have BPD (32). The disproportionately high prevalence of BPD found in clinical settings versus general population can be explained by high level of health services use by BPD patients (33, 34). In general medical settings 6% of primary care patients have BPD (35), which at least in part can be attributed to increased prevalence of chronic medical illnesses in BPD patients (36). These elevated figures highlight importance of timely diagnosis and appropriate treatment of BPD patients in all clinical settings.
Sociodemographic factors
While reports of gender in clinical samples typically reported that BPD is about three times more prevalent in women than in men (37), most epidemiological studies conducted in community samples show similar prevalence rates for both genders (26, 38), although one epidemiologic study confirmed the uneven gender distribution of BPD (23). Gender bias reported in clinical samples seems to be influenced by sampling and diagnostic biases (see Figure 1 Sidebar).
No epidemiologic studies have assessed age of onset of BPD. Extrapolating from onset of self-harm—the most predictive symptom of BPD (44)—the respective age of onset for BPD can be assigned to before age 12 (32.8%), adolescence (13–17 years of age; 30.2%), and early adulthood (18 or older; 37%) (45).
BPD’s prevalence seems to be related to lower education, income, and social class (22). These factors seem to contribute to adversity that may predispose to development of BPD (see subsequent “Biopsychosocial Underpinnings” section) although characteristic BPD symptoms are likely contributors to their poor educational achievement, lower income, and social class as well.
Reports on the marital status of BPD patients in epidemiologic samples indicate they are more likely to be married than Cluster A or C personality disorders patients (22). In clinical samples, probably due to the higher degree of impairment in all personality disorder, BPD patients are similar to other personality disorders in rates of cohabitation or marriage (15.5%) (46); 23% (47) are similar to other personality disorders. However, also consistent with their unstable relationships, BPD patients have higher marital dysfunction (22).
The tendency to be more prevalent in urban areas (i.e., urbanicity) was investigated in two studies, with one reporting somewhat increased prevalence of BPD in urban areas (26) and the other reporting no relationship (24).
Fortunate and unfortunate situations: “Fortunate” means high education (above high school), living together with a partner, and living in the outskirts of a city. “Unfortunate” means the opposite. BPD seems to be more prevalent in unfortunate situations (1.2%), than either in the moderately fortunate (0.8%) or fortunate situation (0.4%) (22).
Culture
BPD has been generally found in every culture where it’s been studied and negative findings were not reported, including the United States (24), China (48), Japan (49), Brazil (50), Norway (26), and India, Kenya, and Europe (51), although reported prevalence rates varies across different countries (e.g., Japan and China samples reported somewhat lower prevalence rates). Cultural factors seem to effect BPD’s presentation. For example, in Japan—where suicide is permissible, substance use is uncommon, and living with ones’ parents is more acceptable—BPD patients report more suicidal behaviors, less substance use, and more interpersonal instability (52). Studies in larger more representative samples are needed to test this conclusion.
Natural History
The course of BPD had been considered very gloomy until research shed light on it. One reason for this was the excessive attention given to the subgroup of BPD patients who were repeat visitors to emergency rooms and inpatient units, the so-called “frequent flyers”. This impression called into question by an original series of research studies that deployed follow-back strategies, i.e. getting in touch with patients who had previously been in treatment at a given institution (53–55). Figure 2 and 3 indicate what was found. Generally, the results showed gradual improvement in psychopathology and a better course than schizophrenia though worse than depression. Because these results were attained from high-income populations, were often from high-prestige institutions using different and sometimes unstandardized assessments and, above all, were retrospective, these results had uncertain credibility.
Figure 2. Typical Course of a Borderline Patient
Adapted from Stone et al. (165).
Figure 3. Fifteen-Year Outcome
From McGlashan (53).
As noted above, we cannot yet identify a particular age of onset except to note that it has been found in children less than 12 and its incidence appears to grow up to early adulthood. Certainly BPD’s impulsive, aggressive, and self-destructive behaviors emerge during adolescence (56), and remain stable (57).
The methodological limitations of the earlier longitudinal studies were addressed in two prospective studies, the McLean Study for Adult Development (MSAD) and the Collaborative Longitudinal Personality Disorder Study (CLPS). Both were NIMH-funded and were initiated in the 1990s with many results that have been published in recent years. Table 4 summarizes some of their design and methodology characteristics. Of note, while the CLPS stopped after 10 years, the MSAD continues to collect data with the most recent reports having 16 years of follow-up. This review will first discuss the course of BPD psychopathology, then social functioning, and then mediators/moderators.
| Characteristic | CLPS | MSAD |
|---|---|---|
| BPD sample size | 175 | 362 |
| Diagnostic assessment | DIPD | DIPD + DIB-R |
| Comparison group(s) | Approx. 500 STPD, AVPD, OCPD, & MDD | Approx. 100 OPD |
| Site(s) | 19 different largely urban outpatient sites | McLean inpatients |
| Demographics | age 18–35, representative ethnicity, SES, and gender | Age 18–35, white, higher SES, female |
| Assessment intervals | monthly | 2 years |
| Follow-up | 10 years | 16+ years |
| Lost to follow-up | 35% | 15% |
a
CLPS: Collaborative Longitudinal Personality Disorders Study; MSAD: McLean Study of Adult Development.
Course of Psychopathology
Figure 4 shows the dramatic, unexpected and prevalent remission of BPD psychopathology as measured by both the decrease in the number of criteria and by an operationalized definition of remission. Of note the course was similar in both studies despite differences in measures and patient sampling. Thus this overall pattern of change can be considered cross-validated. As noteworthy and unexpected was the finding from both studies that when borderline patients remitted, they were apt to remain so. In the CLPS data only about 12% relapsed (defined as returning to greater than 5 criteria for a year or more). More refined analyses by MSAD indicated, as expected, that a larger portion relapsed when shorter periods of time were used to define either remission or relapse.
Figure 4. BPD's Longitudinal Course
Both studies examined the pattern of BPD symptom (criteria) reduction. A report on the 4 year outcome from CLPS suggested what McGlashan (58) labeled a “hybrid model” with some criteria (e.g., self-harm) diminishing more rapidly than others (e.g., affective instability). Similar results were reported from MSAD, where Zanarini (46) adopted the concept of positive (unstable, symptom-like) and negative (stable, trait-like) components. She found that impulsive characteristics and strong unstable relationships resolved earlier than loneliness/emptiness and intolerance of aloneness (59).
Course of Social Functioning
A far more discouraging picture of BPD’s natural course emerged from the examination of social adaptation. The GAF scores of BPD samples remain quite low (about 65) (60), and the rate of those receiving disability support remains quite stable (about 40%) (61). At 10 years follow-up about 30% are married or have stable partnerships and a similar fraction have full-time vocational activities (60). As grim as this seems, the group mean scores for the BPD sample rose significantly on subscales such as self-satisfaction, recreation, and friends. Moreover, these group means hide a considerable amount of variance within the BPD samples and within any particular individual BPD person. Zanarini found that the subsample on disability at 10 years was comprised mainly by a subsample who were not on disability originally (61)! In a longer-term 16-year follow-up, Zanarini has recently reported that 60% of her McLean Hospital-based sample has “recovered,” a term that combines both persisting remission with sustained partnerships (59). This report offers a more hopeful perspective about sustained and substantive changes than have prior reports.
Mediators and Moderators of Course
As described elsewhere (see the “Biopsychosocial Underpinnings” subsection), borderline patients have a neurophysiological system that is primed to make them stress responsive. The longitudinal data support this. Their remissions frequently occur when they leave highly stressful situations (62). This explains why they can regain their composure and sociability so quickly when placed in low stress asylum-like situations. Of note, they report having more stressful events, most particularly interpersonal stressors like rejection, that precede and predict self-harm, suicidality, dissociation, and relapses (63–65).
Predictors of outcome were identified as well. Higher degree of BPD psychopathology, low functioning, and history of childhood sexual abuse predicted slower symptomatic recovery in CLPS (66); older age, childhood sexual abuse, family history of substance use, and poor vocational functioning predicted slower symptomatic recovery in MSAD (67). Some of these predictors are probable moderators (e.g., childhood sexual abuse) whereas others are probable mediators (e.g., low functioning) of the course, though more research is needed to examine these hypotheses.
Longitudinal data cannot tell us much about the effects of treatment but they do document the high utilization of health care resources and the gradual reduction of expensive resources like emergency rooms and hospitals (68, 69). They also document the heavy utilization of medications and especially polypharmacy by borderline patients. The more medications, the worse the course. This probably reflects both overreliance on medications despite their modest effects and that a downhill course evokes more prescription of medications.
Examinations of comorbidity are clinically instructive. Of particular importance is that while effects of MDD on BPD course seem to be negligent, BPD has a highly negative effect on the course of MDD (70), a disorder that co-occurs in about 75% of borderline patients. On the other hand, comorbid cluster B personality disorders, notably antisocial and narcissistic types, seems to slow BPD recovery (67). Results regarding effects of comorbid PTSD are inconclusive (66, 71).
Biopsychosocial Underpinnings
Our understanding of the etiology of BPD has become increasingly complicated, accommodating the influences of not only biology and environment separately, but also the interaction between the two. Earlier etiological accounts of BPD, influenced by prevailing psychoanalytic theory, emphasized early environment or experiences, such as trauma, in the development of BPD. As research on BPD has specified biological factors associated with phenotypic features of the disorder, modern etiological formulations have focused on constitutional factors, associated to distinct genetic and neurophysiological characteristics. This review will consider the early developmental, genetic, and neurobiological factors implicated in the development of BPD, as well as the incorporation of these underpinnings into clinical formulations that have organized its major treatments. In each area, the recent advancements from research are impressive, yet readers should also note that while the research often differentiates BPD from healthy controls, the more demanding designs that would demonstrate specificity, vis-a-vis BPD’s major border disorders (MDD, bipolar disorder, and PTSD) usually still need to be conducted.
Early Development
Early psychoanalytic conceptualizations of BPD identified difficulties with separation from caretakers as a central developmental failure in BPD (72). Both insecure attachment and traumatic separation experiences were theoretically implicated as pathogenic factors contributing to the clinical observation of abandonment fears in BPD (73). These clinical theories prompted empirical investigations that confirmed the association between early caretaking experiences, such as more frequent separations and parental over- or under-involvement, and the diagnosis of BPD (74–76). Subsequent studies specifically demonstrated higher prevalence of sexual abuse in subjects with BPD compared with subjects without BPD, leading to a theory that sexual abuse specifically—and childhood trauma more generally—was a main etiological factor in the development of the disorder and that BPD may be better conceptualized as a chronic or complex form of posttraumatic stress disorder (77, 78). While studies continued to confirm the increased prevalence of childhood trauma among individuals with BPD, they also showed that childhood trauma is neither “necessary or sufficient” for the development of BPD (79), nor accounts for much of the amount of variance in the etiology of the disorder (13, 80, 81).
Prospective longitudinal studies have now clarified that while abuse is significantly associated with personality disorders in general (82) and BPD in particular (83), other environmental and parental factors also contribute significantly to BPD’s development. These include low socioeconomic status, family disruption, life stress, maternal inconsistency in the presence of over-involvement, aversive or hostile parental behaviors, and low parental affection (82–84).
In addition to discrete environmental and parental factors contributing to the etiology of BPD, the nature of transactional process between individuals and caretakers, as codified in attachment styles, have been implicated in the development of BPD. Multiple cross-sectional studies of adult samples with BPD and at least one prospective study have documented the predominance of insecure attachment styles, particularly a combination of preoccupied, disorganized, and fearful styles (83, 85–87). The preoccupied aspects of this combination of styles confers the needy, over-involved, angry, and passive qualities to interactions between individuals and caretakers, whereas the disorganized or fearful aspect captures the contradictory, confused, mistrustful, and disoriented qualities of such interactions. Taken together, these two styles interact to both perpetuate attachment interactions through high levels of involvement as well as potentiate distress and emotional challenge. It is likely that the interaction between these styles heightens vulnerability to adverse caretaking interactions and impairs use of attachment for its regulatory effect.
Genetics - In establishing the genetic basis of BPD, a number of family studies of BPD demonstrated a degree of familiality of the disorder (88). They indicate that the mean prevalence of BPD in first-degree relatives is 11.5%, much higher than in the general population (see Epidemiology section). However, these family study findings could not in themselves differentiate the proportion of etiological variance contributed by genetic and environmental factors (already outlined above). Torgersen and colleagues used twin samples to establish concordance of 35% in monozygotic (MZ) twin pairs and 7% in dizygotic (DZ) pairs, with genetic modeling suggesting additive genetic effects ranging from 0.57 to 0.69 and shared-in-family environmental effects ranging from 0–0.11 (89). Another twin study examined the heritability of component traits of BPD indicated heritability of 45% for affective lability, 49% for cognitive dysregulation, and 48% for insecure attachment (90, 91). Since then one large family and two twin studies assessed the heritability of the component sectors of BPD and used multivariate modeling to determine whether there is a single common latent genetic factor in BPD. They found a range of heritability from 44%–60%, with the remaining variance contributed by individual specific environmental factors (18, 60, 92). This level of genetic influence exceeds the heritability of anxiety disorders and depression, but is less than that of bipolar affective disorder or schizophrenia.
Findings from the limited research on molecular genetics of BPD indicate associations between polymorphisms in genes relevant to the serotonergic and dopaminergic system (see Chanen & Kaess [84] for review). Because polymorphisms in the serotonin transporter gene (5-HTTLPR) have previously established a relationship with affective lability (93), impulsivity (94), and suicide (95) it has been of most interest. However, there remains only limited evidence of the relationship between this polymorphism and BPD, and positive results are inconsistently replicated (84).
Specific predisposing early environmental factors in the etiology of BPD combine with genetic factors to confer varying degrees of vulnerability to the development of BPD. As described above, early childhood adversity in a number of forms, constituting “life stress” in general, contribute to the development of BPD. Recent genetic studies have considered the gene-environment interactions of sensitive genotypes and predisposing environments related to a number of disorders. Functional length polymorphisms of the serotonin transporter gene has been shown to moderate the depressogenic effects of stressful life events (96, 97). In studies of BPD, this short allele polymorphism appears to moderate the effects of stressful life events by decreasing impulsivity (98). Moreover, the genetic influences that contribute to the development of BPD also increase the likelihood of exposure to specific stressful live events (99). In addition, genetic influence effects stress reactivity (100), making some people more likely to develop symptoms following traumatic stress (101). Therefore, while important to distinguish the unique contributions of environmental and genetic forces contributing to the etiology of BPD, it is critical to consider interactional effects between the two.
Neurobiology
Neurobiological research has begun to elucidate specific brain and neurohormonal features that underpin the phenomenological characteristics of BPD. Neuroimaging studies of BPD have primarily focused on examining the neural basis of the distinct emotional dysregulation characteristic of the disorder. The early wave of these studies documented hyperreactivity in limbic structures, primarily the amygdala (102, 103), while later studies began to describe distinct dysfunction in prefrontal and frontolimbic activity as the larger mechanism behind emotional dysregulation in BPD (104–106). These data support the notion that emotional intensity and dysregulation in BPD is the manifestation of failures of top-down frontal control processes that should modulate the effects of the bottom-up hyperreactive limbic structures. Ruocco and colleagues meta-analyzed the existing neuroimaging literature, concluding that BPD subjects show: 1) activation of a diffuse network of structures in negative emotion processing extending from the amygdala, anterior cingulate cortex, medial and dorsolateral prefrontal cortex, superior temporal gyrus, posterior cingulated, and cerebellum; 2) decreased activation of regions extending from the amygdala to the anterior cingulate and dorsolateral prefrontal cortex; and 3) increased activation of greater insula and posterior cingulate cortex (107).
The specific finding of reduced activation of the anterior cingulate cortex in negative emotional processing distinguishes BPD from MDD (108), suggesting an important distinction between these disorders. Also, the activity of the insular cortex may underpin a range of symptom sectors in BPD, as this region of the brain has been shown to be involved in the processing of emotional and physical pain, self-awareness, and social cognitive processes involved in empathy and adherence to or violation of social norms. Differences in neural activity in the insular cortex have been demonstrated in the context of difficulties among BPD subjects to sustain and repair cooperation during social exchange (109). Further research is needed to clarify the overlap of dysfunction in the brain areas implicated in negative emotion processing and interpersonal vulnerabilities in BPD, as these two sectors are most defining of the disorder.
Neuropsychological tests that assess actual brain functioning complement the localization results from imaging studies. They have confirmed dysfunction in such areas as prefrontal (primarily) and additionally, in temporal and parietal cortex (110, 111). Interestingly, brain lesions in these areas do not produce BPD symptoms (112), suggesting that brain abnormalities in BPD patients are more related to abnormal function of these areas.
While neuroimagining research has focused on mechanisms of abnormal emotion processing, research on neuropeptides has shed some light on the stress and interpersonal sensitivity of BPD. As discussed above, individuals with BPD commonly experience more early and adult life stress, which may both interact with and be potentiated by genetic factors, in the context of unstable and insecure attachments. As noted earlier (see “Natural History” and “Treatment and Outcome” subsections) many features of BPD are stress reactive. Biologically, elevated cortisol responses to psychosocial stress and dysregulated feedback responses in BPD subjects suggest overall impaired physiological management of stress (113). Neuropeptide systems involving opioids and oxytocin also effect stress responses show altered functioning in BPD (see Table 5). Both opioids and oxytocin also facilitate prosocial tendencies. Oxytocin administration is associated with enhanced performance on “mind-reading” or interpreting mental states from social cues (115) and collaboration in social exchange tasks in normal subjects (116). Strikingly, the administration of oxytocin to subjects with BPD actually increased mistrust and decreased cooperation in a social exchange paradigm (116). This suggests that the BPD’s oxytocin system may produce a paradoxical tendency toward mistrust and interpersonal instability in social activity rather than the kind of affiliation that normal oxytocin responses cause.
| Neuropeptide | Effects on Stress Regulation | Effects of Interpersonal Behaviors | Findings in BPD |
|---|---|---|---|
| Opioids | Regulates responses to stressor which induce physical, emotional, or social painActivates HPA axis | Mediates “social affect”Modulates responses to distress related to separation or rejection and relief related to reunionReinforces social interactionInvolved in self-soothing responses related to separation by dampening fear and stress responses | ↓ basal opioid levels as explanation for chronic dysphoria and emptiness, as well as difficulty self-soothing and tendency to misuse opiates↓ basal opioid levels and ↓ pain perception associated with self-injuryOpioid receptor antagonists may ↓ self-injury↓ opioid release in context of sadness in orbitofrontal cortex, caudate, and accumbens; probable relationship to emotional dysregulation in BPDPreliminary evidence that polymorphisms of particular opioid receptor genes are related to preoccupation with attachment and identity problems |
| Oxytocin | Inhibits HPA axis activityDiminishes stress response | Central to maternal, pair-bonding, and prosocial tendencies (e.g., licking, grooming, nursing in animals; monogamy, affection, maternal gaze in humans)Enhances trust and collaborationImplicated in reading facial expressions/mentalizingInvolved in encoding of memories of positive social interactions | ↓ urinary and CSF levels in individuals with history of childhood maltreatment and early separationsWhile nonborderline subjects demonstrate enhanced collaboration in an economic exchange paradigm upon administration of oxytocin, subjects with BPD, defect more and collaborate less |
a
Adapted from Stanley and Siever (114).
Biopsychosocial Treatment Implications
Both environmental and endogenous processes contribute to the etiology and clinical presentation of BPD. While early childhood adversity, dysfunctional caretaking, and general early life stress may function as robust etiological forces in the development of BPD, genetics, in addition to disturbed regulatory functions of brain and neuropeptide systems, may prime individuals to be more prone to pathological responses to environmental life stress.
Assessment & Differential Diagnosis
As noted earlier, the presence of a reliable structured interview for establishing the BPD diagnosis set the stage for it being adopted into DSM-III in 1980. This interview, the Diagnostic Interview for Borderlines (DIB) divides BPD psychopathology into sectors of affect, cognition, behavior, and interpersonal relationships and the diagnosis requires scoring in at least 3 of these 4 sectors (9). In the aftermath of DSM-III a number of reliable structured interviews were developed for assessing the specific criteria for BPD and for all of the other personality disorders (117–120). Structured interviews of the DSM criteria have yielded much of the acquired knowledge about the disorder. Nonetheless, reliance on a polythetic criteria count has been subject to criticism because there are 256 possible combinations by which to attain the BPD diagnosis and hence, there is the danger of great heterogeneity within samples. While this is statistically true, in clinical samples there is much variance in the frequency in which the criteria occur, so that it is rare for a patient to meet criteria for BPD without having both affective and interpersonal criteria—the criteria which represent the core of BPD (121). There are, however, advocates for changing the diagnostic assessment in several ways. One is to use a prototypic description, thereby capturing an overall clinical impression of “borderlineness” (122). The other, endorsed by many clinical and research leaders, is to return to a DIB-like requirement that patients score in multiple sectors rather than by criteria count (21).
Again, as noted earlier, the differential diagnostic issues that surround BPD have undergone changes. The original question as to its being an atypical form of schizophrenia were rather quickly dismissed by virtue of the modest overlap in phenomenology and the failure of BPD to show any familial or genetic connection to schizophrenia. The question of BPD being an atypical form of affective disorder (123, 124) has proven more difficult to dispel. The fact that most (approximately 75%) BPD patients have lifetime MDD and they all present with complaints of severe dysphoria is difficult to ignore. Phenomenologically the borderlines are clearly distinct from those with depression because of their interpersonal and behavioral characteristics. But could these be due to depression? The evidence that the familial relationship is weak (88) and that BPD’s depression doesn’t respond to antidepressants (125, 126); see Treatment & Outcome section below) has sustained the idea of their separateness. Without question, psychiatrists give many BPD patients a MDD diagnosis. There will be fewer questions about reimbursement and they feel better trained to offer medication treatment than psychosocial therapies.
With respect to bipolar disorder, the overlap in phenomenology is more evident; both disorders are emotionally and behaviorally dysregulated. The dramatic expansion in diagnosing bipolar “spectrum” disorders has meant that this has become a common way that borderline patients get mislabeled (127, 128) and for the same unfortunate reasons that the MDD diagnosis is given. Here, however, the co-occurrence of BPD with bipolar disorders is much less (∼15%), they appear independent in their course (66), and the familial relationship is very weak (88). The recent evidence that mood stabilizers benefit–albeit modestly and inconsistently–borderline patients (129, 130; see “Treatment and Outcomes” section) will continue to fuel questions about the relationship between these disorders, and sadly, will continue to encourage psychiatrist to rely too much on medication treatments.
A final differential diagnostic question of importance involves PTSD (15). When the high prevalence of trauma in the childhoods of borderline patients (approximately 70%) was reported in the 1980s (see “Biopsychosocial Underpinnings” section), it was suggested that BPD may be an atypical and severe form of PTSD. Against this idea was the fact that a significant number of BPD patients don’t have such trauma, and that borderline patients, unlike PTSD, respond to treatments that focus on feelings, not trauma, and challenge them to take control of their lives. It is now recognized that severe early trauma may have sequelae that include a BPD-like syndrome, called “Complex PTSD”, where trauma is central and requires priority. These patients have trouble with trust and cognitive processing that make BPD treatments for them ineffective. For most BPD patients, as noted earlier, their trauma is superimposed on a genetically determined preexisting sensitivity, and while such children will have psychophysiological difficulties processing trauma and trouble communicating about such adversities, they can as adults benefit from BPD’s therapies.
Treatment and Outcome
BPD Treatment and Treatment Outcome
Individual psychotherapy has been always seen as the primary treatment for BPD. Initially, dominated by the psychoanalytic paradigm, BPD was conceptualized in terms of specific structural deficits in the personality. This approach prescribed long-term, individual, intensive treatment aimed to restructure personality and thus eliminate BPD symptoms. This fueled therapeutic enthusiasm, which unfortunately was not confirmed by clinical experience (131). Improvements were rare exceptions rather than the rule and most such treatments were, in retrospect, doomed to fail due to the toxic effects of the psychoanalytic model, e.g., being unstructured, inactive, and patient-led.
In the early 1990s a second generation of treatments began to emerge that were structured, of 12–18 months duration, and were goal/symptom-oriented. They were described in treatment manuals, often involved a team of therapists, and were tested in randomized control trials (RCTs). Four of these empirically-validated treatments that we believe have the most recognition and usage are featured in Table 6.
| Treatment (supportive trials/total trials) | Description | Empirical support | Training mechanisms |
|---|---|---|---|
| DBT (13/13) | Behavioral therapy that teaches distress tolerance, emotional regulation, interpersonal effectiveness, and mindfulness; therapist is available to manage crisis; therapy involves 1/week individual and 2/week group therapy; therapists meet 1/week group consultation | Reviewed in Gunderson et al. (146) | Workshop through Behavioral Tech (www.behavioraltech.org) and a year-long supervision |
| MBT (3/3) | Assuming “not knowing”, curious stance about the patient, therapist teaches the skill of thinking about oneself and others in terms of meaningful intentional states; therapy involves 1/week individual and 2/week group therapy; therapists meet 1/week group consultation | Bateman and Fonagy (144, 164); Jørgensen et al. (136) | Workshop with Dr. Bateman and year-long supervision |
| TFP (2/3) | Attachment-based therapy that promotes integrated thinking about self and others through use of interpretation of motives and distortions in perception of self and others, including the therapist; it involves 2/week individual therapy; therapists meet for weekly supervision | Clarkin et al. (145); Doering et al. (133); Giessen-Bloo et al. (149) | Workshop through Personality Disorders Institute (www.borderlinedisorders.com) and a year-long supervision |
| GPM (1/1) | Individual case management mixing dynamic and behavioral models; it focuses on interpersonal and situational stressors; therapy involves 1/week individual therapy with 2nd (group, family, mediation) modality encouraged; therapists meet for weekly supervision | McMain et al. (143) | Workshop with Dr. Gunderson; supervision is desired |
Comparison of the outcomes shows that all evidence-based treatments (EBTs) for BPD produce similar improvements in suicidality, deliberate self-harm, depression, and decreased use of emergency rooms, hospitalizations, and medications. Improvement of functioning, especially vocational functioning, and quality of life is modest (132–136). These results mirror the course of BPD reported in longitudinal studies (see “Natural History” section).
| Principle | Description |
|---|---|
| A primary clinician | Primary clinician assesses progress, monitors safety and oversees communications. Is active and sometimes directive. |
| An agreed-upon treatment structure | Goals and roles should be clearly defined, especially personal limits and guidelines to handle crises. |
| Connect acts and feelings to events. | Therapist explores problematic behaviors in context of precipitating events, thoughts and feelings. |
| Support | Treaters provide validation of the patient’s distress and express hope regarding patient’s ability to change. |
| Patient is actively involved | The patients need to know that their progress depends upon their active efforts to take control over their feelings, behaviors, and future. Therapy helps the patient to become more involved. |
| Therapist is active | Clinicians are active (interrupt silences, digressions), focus on here-and-now (including parents’ angry or dismissive responses), and help explores thoughts, feelings, and behaviors. Responds to safety issues with concern, but resists cautiously. |
| Therapist monitors countertransference, consults with colleagues | Idealization and devaluation are part of relational repertoire of the patient to which the therapist sometimes responds with inclinations to rescue or punish. These reactions (i.e. countertransference), though expectable, can interfere with treatment. Consulting a colleague can help in managing these feelings. |
Supportive therapies have often been used as comparison treatments when testing more constricted theory-driven therapies such as DBT, MBT, and TFP. Among these are General Psychiatric Management (143), Structured Clinical Management (144), Supportive Psychoanalytic Psychotherapy (145), and Supportive Group Therapy (136). All of these approaches reduced symptoms through focus on building coping skills, problem-solving, psychoeducation, and validation. These approaches have yielded surprisingly similar outcomes to specialized EBTs (e.g., DBT, TFP, MBT) and yet they were easier to learn and less intensive. Thus, they have emerged as a more practical treatment for clinicians who are not BPD specialists and for clinics where implementation of more specialized therapies is not feasible (146).
Other treatments for BPD
Today there are 13 psychosocial interventions with a least one RCT supporting their effectiveness (for a review see Stoffers et al. [147]). Most lack published treatment manuals, training mechanisms, or much clinical use outside of the research trials. Some of the more recognized and/or potentially useful of these treatments are Schema Focused Psychotherapy (148), Cognitive Analytic Therapy (149), and Systems Training for Emotional Predictability and Problem Solving (150).
Multimodel Treatment
There are clinical, conceptual, and empirical reasons to view multimodel, or split-treatments as effective. First, different modalities are likely to compliment and augment each other. Second, members of the team are a natural source of mutual support. Third, multimodel treatment provides BPD patients with outlets to express anger and disappointment without leaving treatment (151). Finally, as noted, involvement of the multiple treaters is supported by RCTs for DBT and MBT.
Family Treatment
There are multiple reasons to involve families of BPD patients. First, destructive family dynamics are a major contributor to the discontinuation of treatment by BPD patients (152). Second, families experience significant distress related to the BPD patient’s problems (153). Third, whether or not the families have a role in the BPD patient’s adversity, sometimes family members become entangled in dysfunctional relationships with each other and in such a way impede treatment. Effective family intervention provides psychoeducation regarding BPD, its origin, course, and treatment. It teaches problem solving skills to address difficult dynamics as well as validation and other communication skills to deal with the emotional reactivity of the BPD relative (154).
Group Treatment
Group therapy is an important component of some EBTs (i.e., DBT, MBT). Not only groups offer a valuable opportunity to learn how to share feelings, be empathic, as well as deal with conflict and share attention, but also provide feedback to each other. Group treatment for BPD were supported not only in trials for DBT and MBT (147), but also as a separate treatment modality for BPD (136, 155, 156).
Pharmacotherapy
Medications only have a modest effect on BPD and their role is adjunctive in BPD treatment. It is important to recognize that many symptoms, such as frantic efforts to avoid abandonment, emptiness, identity disturbance, and dissociation do not respond to pharmacotherapy (157). Prescription of medication can help build positive alliance with the BPD patient (151). Selection of medication types is complicated. Although initial reports demonstrated modest effectiveness on depression and impulsivity by selective serotonin reuptake inhibitors (SSRIs) (158), more recent meta-analyses suggests that their overall effects are similar to placebo (126, 157). Atypical neuroleptics showed slightly better effectiveness, particularly in improving mood instability, anxiety, anger, impulsivity, and cognitive symptoms (126, 157). Metabolic side-effects, especially, weight gain and risk of diabetes made them less desirable by patients and decrease compliance. Mood stabilizers have shown some effectiveness in improving mood instability, anger, and impulsivity (157), but such possible side effects as kidney toxicity and sedation (with lithium), cognitive side effects (with topamax) or skin rash (with lamotrigine) reduce compliance. Use of benzodiazepines have not received empirical support and are generally contraindicated for borderline patients because of risks of behavioral disinhibition (159), addiction, and overdose. Pharmacotherapy has a slightly stronger basis for treatment of comorbid disorders such as bipolar disorder or substance dependence (e.g., suboxone for opiate dependence (160) or antabuse for alcohol dependence (161), though concurrent psychotherapy that addresses both BPD and either of these comorbid conditions is critical for therapeutic process (162). Major depressive disorder in BPD only modestly responds to medications (157, 163), and it usually improves only after improvement of BPD (70). These findings underscore the excessive and potentially overuse of this class of medications for borderline patients.
Important principles of psychopharmacological case management are 1) Create realistic expectations, namely, medications are not likely to produce curative change and their effects are difficult to assess. 2) Enlist active involvement of the patient in identifying treatment targets, maintaining compliance, ensuring safety, evaluating benefits regarding medications and side-effects, and reading about the prescribed medications. 3) Use independent judgment regarding the effectiveness of medications, since BPD patients are likely to value or devalue medications in deference to their perception of the relationship with the prescriber, e.g., fear of being controlled or of not being cared for, as well as their expectations of being cured (151).
Levels of Care
Determination of the appropriate level of care is an issue all psychiatrists need to address (see Table 8). The central principle is to keep treatment at the least restrictive level of care, i.e., provide enough structure to keep the patient safe but enough exposure to problems that they remain engaged in working on treatment targets. Higher levels of care provide safety and containment of crises, although responding to dramatized expressions of distress by unnecessarily placing a BPD patient in a higher level of care is an over-reaction that will reinforce avoidance and encourage the recurrence of crises (151). On the other hand, if the level of care is inappropriately low, the BPD patient will spiral into panic and desperation. Impulsive behaviors will escalate and the treatment will stall. Determination of the optimal level of care is based on clinical experience, rather than an empirically established algorithm, since research in this area is undercut by methodological and ethical limitations (Figure 5 Sidebar).
| Level of Care | Goals | Length | Clinical Tasks | Treatment modalities | Empirical Support (quality) |
|---|---|---|---|---|---|
| Hospital 24 h/d 7 d/wk | Making therapy possible | 1–2 weeks | Safety/crisis stabilization, assessment, treatment planning | Case management, medications, psychoeducation | No RCTs, only pre-post studies (moderate) |
| Residential/partial hospital 10–20 h/wk | Basic socialization | 1–6 weeks | Daily living skills, social skills, impulse control, assist with community living, alliance building, | Case management, groups (CBT, self-assessment), psychoeducation | One RCT and some pre-post studies (weak) |
| Intensive outpatient 4–10 hr/wk | Behavioral change | 3–12 months | Further socialization, impulse control, alliance building | Case management, groups (skills, interpersonal), individual psychotherapy | Nine RCTs (strong) |
| Outpatient <4 h/wk | Interpersonal growth | As long as needed | Introspection, agency, skill generalization, intrapsychic change, alliance building | Case management, groups (interpersonal, mentalization), individual psychotherapy | 20 RCTs (strong) |
Future Directions
At this time the issues that challenge the continued growth of knowledge about borderline personality disorder are very different than those that the diagnosis faced when it entered the DSM-III 33 years ago. At that time the issues were diagnostic validity and treatability. The first of these issues has been convincingly answered by research that has established the syndrome’s latent unifying psychometric coherence and its surprisingly unitary latent genetic structure. Moreover, its treatability has been repeatedly demonstrated by a variety of treatments that have basic and replicable overlapping characteristics. The major problem borderline patients face in the current era is not due to not knowing how to help them, it is the problem of untrained treaters who underdiagnose and overmedicate them.
The BPD diagnosis is now confronted by other and very complicated issues. This review has identified and highlighted some of these. Central to these is the persisting need to determine what is the core of BPD psychopathology. The two candidates are failed emotional regulation and interpersonal hypersensitivity. While both candidates are lending themselves to neurobiological discoveries there remains a conspicuous reluctance by government agencies and by pharmaceutical companies to invest in this research. This in turn is directly related to another persisting and complex issue, i.e., the stigma that continues to surround the diagnosis. Here is a frontier for which education, starting within the mental health professions can bring about change. A third major scientific frontier that becomes evident from this review is the identification of early markers of risk for BPDs development that will allow earlier interventions. Such interventions are probably most likely to be psychosocial in recognition of the preborderline child’s excessive sensitivity to stress. Public awareness and research funding are needed.
Other frontiers identified in this review involve treatment of BPD. There exists a major need for the next generation of treatments to become more usable by nonexperts and part of the basic training given by all mental health professionals. Another implication is that the next generation of treatments needs to affect changes in vocational and more generally in the social functioning of BPD patients. Social rehabilitation processes should be major components of treatment. A related implication is that future measures of outcome should assess BPD’s neurobiological and psychological handicaps. Treatments may be best organized around helping individuals manage stress through case management interventions as well as psychotherapeutic interventions designed to enhance prefrontal activity in processing emotions as well as those designed to enhance attachment by interrupting dysfunctional social tendencies which may be in part driven by altered neurobiological responses.
References
1.
Stern A: Psychoanalytic investigation and therapy in the borderline group of neuroses. Psychoanal Q 1938; 7:467–489
2.
Knight RP: Borderline states. Bull Menninger Clin 1953; 17:1–12
3.
Grinker R, Werble B, Drye R: The Borderline Syndrome: A Behavioral Study of Ego Functions. New York, Basic Books, 1968
4.
Kety SS, Rosenthal DH, Wender P, Schulsinger F: The types and prevalence of mental illness in the biological and adoptive families of adopted schizophrenics, in The Transmission of Schizophrenia. Edited by, Rosenthal D, Kety S. New York, Pergamon Press, 1968, pp 345–362
5.
Kernberg O: Borderline personality organization. J Am Psychoanal Assoc 1967; 15:641–685
6.
Kernberg O: The treatment of patients with borderline personality organization. Int J Psychoanal 1968; 49:600–619
7.
Gunderson JG, Singer MT: Defining borderline patients: an overview. Am J Psychiatry 1975; 132:1–10
8.
Gunderson JG, Kolb JE, Austin V: The diagnostic interview for borderline patients. Am J Psychiatry 1981; 138:896–903
9.
Zanarini MC, Gunderson JG, Frankenburg FR, Chauncey DL: The revised diagnostic interview for borderlines: discriminating BPD from other axis II disorders. J Pers Disord 1989; 3:10–18
10.
Gunderson JG, Kolb JE: Discriminating features of borderline patients. Am J Psychiatry 1978; 135:792–796
11.
Clifton A, Pilkonis PA: Evidence for a single latent class of Diagnostic and Statistical Manual of Mental Disorders borderline personality pathology. Compr Psychiatry 2007; 48:70–78
12.
Fossati A, Madeddu F, Maffei C: Borderline Personality Disorder and childhood sexual abuse: a meta-analytic study. J Pers Disord 1999; 13:268–280
13.
Sanislow CA, Grilo CM, Morey LC, Bender DS, Skodol AE, Gunderson JG, Shea MT, Stout RL, Zanarini MC, McGlashan TH: Confirmatory factor analysis of DSM-IV criteria for borderline personality disorder: findings from the collaborative longitudinal personality disorders study. Am J Psychiatry 2002; 159:284–290
14.
Taylor J, Reeves M: Structure of borderline personality disorder symptoms in a nonclinical sample. J Clin Psychol 2007; 63:805–816
15.
Gunderson JG: Borderline personality disorder: ontogeny of a diagnosis. Am J Psychiatry 2009; 166:530–539
16.
Krueger RF, Skodol AE, Livesley WJ, Shrout PE, Huang Y: Synthesizing dimensional and categorical approaches to personality disorders: refining the research agenda for DSM-V Axis II. Int J Methods Psychiatr Res 2007; 16(Suppl 1):S65–S73
17.
Kendler KS, Myers J, Reichborn-Kjennerud T: Borderline personality disorder traits and their relationship with dimensions of normative personality: a web-based cohort and twin study. Acta Psychiatr Scand 2011; 123:349–359
18.
Hudson JI, Zanarini MC, Mitchell KS, Choi-Kain LW, Gunderson JG: The association of familial internalizing and externalizing liability factors to borderline personality disorder. Unpublished
19.
DePue RA, Lenzenweger MF: Personality disorders as emergent phenotypes from multiple interaction neurobehavioral systems, in (Eds), Handbook of Personality Disorders, 2nd Ed. Edited by Clarkin JF, Lenzenweger MF. New York, Guilford Press, 2005
20.
Kendler KS, Aggen SH, Czajkowski N, Røysamb E, Tambs K, Torgersen S, Neale MC, Reichborn-Kjennerud T: The structure of genetic and environmental risk factors for DSM-IV personality disorders: a multivariate twin study. Arch Gen Psychiatry 2008; 65:1438–1446
21.
Gunderson JG: Revising the borderline diagnosis for DSM-V: an alternative proposal. J Pers Disord 2010; 24:694–708
22.
Torgersen S: Epidemiology, in The Oxford Handbook of Personality Disorders. Edited by Wideger T. New York, Oxford University Press, 2012, pp 186–205
23.
Trull TJ, Jahng S, Tomko RL, Wood PK, Sher KJ: Revised NESARC personality disorder diagnoses: gender, prevalence, and comorbidity with substance dependence disorders. J Pers Disord 2010; 24:412–426
24.
Grant BF, Chou SP, Goldstein RB, Huang B, Stinson FS, Saha TD, Smith SM, Dawson DA, Pulay AJ, Pickering RP, Ruan WJ: Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2008; 69:533–545
25.
Lenzenweger MF, Loranger AW, Korfine L, Neff C: Detecting personality disorders in a nonclinical population. Application of a 2-stage procedure for case identification. Arch Gen Psychiatry 1997; 54:345–351
26.
Torgersen S, Kringlen E, Cramer V: The prevalence of personality disorders in a community sample. Arch Gen Psychiatry 2001; 58:590–596
27.
Grant BF, Stinson FS, Hasin DS, Dawson DA, Chou SP, Anderson K: Immigration and lifetime prevalence of DSM-IV psychiatric disorders among Mexican Americans and non-Hispanic whites in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61:1226–1233
28.
Johnson JG, Cohen P, Kasen S, Skodol AE, Oldham JM: Cumulative prevalence of personality disorders between adolescence and adulthood. Acta Psychiatr Scand 2008; 118:410–413
29.
Zimmerman M, Chelminski I, Young D: The frequency of personality disorders in psychiatric patients. Psychiatr Clin North Am 2008; 31:405–420, vi
30.
Korzekwa MI, Dell PF, Links PS, Thabane L, Webb SP: Estimating the prevalence of borderline personality disorder in psychiatric outpatients using a two-phase procedure. Compr Psychiatry 2008; 49:380–386
31.
Hull JW, Yeomans F, Clarkin J, Li C, Goodman G: Factors associated with multiple hospitalizations of patients with borderline personality disorder. Psychiatr Serv 1996; 47:638–641
32.
Hayashi N, Igarashi M, Imai A, Osawa Y, Utsumi K, Ishikawa Y, Tokunaga T, Ishimoto K, Harima H, Tatebayashi Y, Kumagai N, Nozu M, Ishii H, Okazaki Y: Psychiatric disorders and clinical correlates of suicidal patients admitted to a psychiatric hospital in Tokyo. BMC Psychiatry 2010; 10:109 doi: 10.1186/1471-244X-10-109
33.
Bender DS, Skodol AE, Pagano ME, Dyck IR, Grilo CM, Shea MT, Sanislow CA, Zanarini MC, Yen S, McGlashan TH, Gunderson JG: Prospective assessment of treatment use by patients with personality disorders. Psychiatr Serv 2006; 57:254–257
34.
Zanarini MC, Frankenburg FR, Khera GS, Bleichmar J: Treatment histories of borderline inpatients. Compr Psychiatry 2001; 42:144–150
35.
Gross R, Olfson M, Gameroff M, Shea S, Feder A, Fuentes M, Lantigua R, Weissman MM: Borderline personality disorder in primary care. Arch Intern Med 2002; 162:53–60
36.
Frankenburg FR, Zanarini MC: Obesity and obesity-related illnesses in borderline patients. J Pers Disord 2006; 20:71–80
37.
Widiger T, Trull T: Borderline and narcissistic personality disorders, in Comprehensive book of psychopathology. Edited by Sucker PB, Adams HE. New York Plenum, 1993
38.
Lenzenweger MF, Lane MC, Loranger AW, Kessler RC: DSM-IV personality disorders in the national comorbidity survey replication. Biol Psychiatry 2007; 62:553–564
39.
Zlotnick C, Rothschild L, Zimmerman M: The role of gender in the clinical presentation of patients with borderline personality disorder. J Pers Disord 2002; 16:277–282
40.
Skodol AE, Bender DS: Why are women diagnosed borderline more than men? Psychiatr Q 2003; 74:349–360
41.
Henry KA, Cohen CI: The role of labeling processes in diagnosing borderline personality disorder. Am J Psychiatry 1983; 140:1527–1529
42.
Sprock J: Abnormality ratings of the DSM-III-R personality disorder criteria for males vs. females. J Nerv Ment Dis 1996; 184:314–316
43.
Morey LC, Ochoa ES: An investigation of adherence to diagnostic criteria. J Pers Disord 1989; 3:180–192
44.
Grilo CM, Pagano ME, Skodol AE, Sanislow CA, McGlashan TH, Gunderson JG, Stout RL: Natural course of bulimia nervosa and of eating disorder not otherwise specified: 5-year prospective study of remissions, relapses, and the effects of personality disorder psychopathology. J Clin Psychiatry 2007; 68:738–746
45.
Zanarini MC, Frankenburg FR, Hennen J, Reich DB, Silk KR: Prediction of the 10-year course of borderline personality disorder. Am J Psychiatry 2006; 163:827–832
46.
Zanarini MC, Frankenburg FR, Hennen J, Reich DB, Silk KR: The McLean Study of Adult Development (MSAD): overview and implications of the first six years of prospective follow-up. J Pers Disord 2005; 19:505–523
47.
Gunderson JG: Clinical Report: Borderline Personality Disorder. N Engl J Med 2011; 5:2037–2042
48.
Wang, et al. 2012
49.
Ikuta N, Zanarini MC, Minakawa K, Miyake Y, Moriya N, Nishizono-Maher A: Comparison of American and Japanese outpatients with borderline personality disorder. Compr Psychiatry 1994; 35:382–385
50.
Pondé MP, Freire AC, Mendonça MS: The prevalence of mental disorders in prisoners in the city of Salvador, Bahia, Brazil. J Forensic Sci 2011; 56:679–682
51.
Loranger AW, Sartorius N, Andreoli A, Berger P, Buchheim P, Channabasavanna SM, Coid B, Dahl A, Diekstra RF, Ferguson B, et al.: The International Personality Disorder Examination. The World Health Organization/Alcohol, Drug Abuse, and Mental Health Administration international pilot study of personality disorders. Arch Gen Psychiatry 1994; 51:215–224
52.
Moriya N, Miyake Y, Minakawa K, Ikuta N, Nishizono-Maher A: Diagnosis and clinical features of borderline personality disorder in the east and west: a preliminary report. Compr Psychiatry 1993; 34:418–423
53.
McGlashan TH: The Chestnut Lodge follow-up study. III. Long-term outcome of borderline personalities. Arch Gen Psychiatry 1986; 43:20–30
54.
Plakun EM: Prediction of outcome in borderline personality disorder. J Personal Disord 1991; 5:93–101
55.
Stone MH: The Fate of Borderline Patients. New York, Guilford, 1990
56.
Goodman M, Patil U, Triebwasser J, Diamond E, Hiller A, Hoffman P, Goldberg S, Koenigsberg H, Siever L, New A: Parental viewpoints of trajectories to borderline personality disorder in female offspring. J Pers Disord 2010; 24:204–216
57.
Chanen AM, Jackson HJ, McGorry PD, Allot KA, Clarkson V, Yuen HP: Two-year stability of personality disorder in older adolescent outpatients. J Pers Disord 2004; 18:526–541
58.
McGlashan TH, Grilo CM, Sanislow CA, Ralevski E, Morey LC, Gunderson JG, Skodol AE, Shea MT, Zanarini MC, Bender DS, Stout RL, Yen S, Pagano ME: Two-year prevalence and stability of individual DSM-IV criteria for schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders: toward a hybrid model of axis II disorders. Am J Psychiatry 2005; 162:883–889
59.
Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G: Attainment and stability of sustained symptomatic remission and recovery among patients with borderline personality disorder and axis II comparison subjects: a 16-year prospective follow-up study. Am J Psychiatry 2012; 169:476–483
60.
Gunderson JG, Stout RL, McGlashan TH, Shea MT, Morey LC, Grilo CM, Zanarini MC, Yen S, Markowitz JC, Sanislow C, Ansell E, Pinto A, Skodol AE: Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study. Arch Gen Psychiatry 2011; 68:827–837
61.
Zanarini MC, Jacoby RJ, Frankenburg FR, Reich DB, Fitzmaurice G: The 10-year course of social security disability income reported by patients with borderline personality disorder and axis II comparison subjects. J Pers Disord 2009; 23:346–356
62.
Gunderson JG, Bender D, Sanislow C, Yen S, Rettew JB, Dolan-Sewell R, Dyck I, Morey LC, McGlashan TH, Shea MT, Skodol AE: Plausibility and possible determinants of sudden “remissions” in borderline patients. Psychiatry 2003; 66:111–119
63.
Shea MT: Life events and change in course of personality disorders. Presented May 24, 2007 at Am Pyschoanalytic Association Annual Meeting, San Diego, California
64.
Yen S, Pagano ME, Shea MT, Grilo CM, Gunderson JG, Skodol AE, McGlashan TH, Sanislow CA, Bender DS, Zanarini MC: Recent life events preceding suicide attempts in a personality disorder sample: findings from the collaborative longitudinal personality disorders study. J Consult Clin Psychol 2005; 73:99–105
65.
Brodsky BS, Groves SA, Oquendo MA, Mann JJ, Stanley B: Interpersonal precipitants and suicide attempts in borderline personality disorder. Suicide Life Threat Behav 2006; 36:313–322
66.
Gunderson JG, Daversa MT, Grilo CM, McGlashan TH, Zanarini MC, Shea MT, Skodol AE, Yen S, Sanislow CA, Bender DS, Dyck IR, Morey LC, Stout RL: Predictors of 2-year outcome for patients with borderline personality disorder. Am J Psychiatry 2006; 163:822–826
67.
Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G: The 10-year course of psychosocial functioning among patients with borderline personality disorder and axis II comparison subjects. Acta Psychiatr Scand 2010; 122:103–109
68.
Bender DS, Dolan RT, Skodol AE, Sanislow CA, Dyck IR, McGlashan TH, Shea MT, Zanarini MC, Oldham JM, Gunderson JG: Treatment utilization by patients with personality disorders. Am J Psychiatry 2001; 158:295–302
69.
Zanarini MC, Frankenburg FR, Hennen J, Silk KR: Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry 2004b; 65:28–36
70.
Gunderson JG, Morey LC, Stout RL, Skodol AE, Shea MT, McGlashan TH, Zanarini MC, Grilo CM, Sanislow CA, Yen S, Daversa MT, Bender DS: Major depressive disorder and borderline personality disorder revisited: longitudinal interactions. J Clin Psychiatry 2004; 65:1049–1056
71.
Shea MT, Stout RL, Yen S, Pagano ME, Skodol AE, Morey LC, Gunderson JG, McGlashan TH, Grilo CM, Sanislow CA, Bender DS, Zanarini MC: Associations in the course of personality disorders and Axis I disorders over time. J Abnorm Psychol 2004; 113:499–508
72.
Modell A: Primitive object relationships and the predisposition to schizophrenia. Int J Psychoanal 1963; 44:282–291
73.
Masterson JF: Treatment of the adolescent with borderline syndrome. A problem in separation-individuation. Bull Menninger Clin 1971; 35:5–18
74.
Bradley SJ: The relationship of early maternal separation to borderline personality in children and adolescents: a pilot study. Am J Psychiatry 1979; 136(4A):424–426
75.
Gunderson JG, Kerr J, Englund DW: The families of borderlines. A comparative study. Arch Gen Psychiatry 1980; 37:27–33
76.
Frank H, Hoffman N: Borderline empathy: an empirical investigation. Compr Psychiatry 1986; 27:387–395
77.
Herman J: Truama and Recovery. New York, Basic Books, 1992
78.
Herman JL, Perry JC, van der Kolk BA: Childhood trauma in borderline personality disorder. Am J Psychiatry 1989; 146:490–495
79.
Gunderson JG, Sabo AN: The phenomenological and conceptual interface between borderline personality disorder and PTSD. Am J Psychiatry 1993; 150:19–27
80.
Bierer LM, Yehuda R, Schmeidler J, Mitropoulou V, New AS, Silverman JM, Siever LJ: Abuse and neglect in childhood: relationship to personality disorder diagnoses. CNS Spectr 2003; 8:737–754
81.
Bandelow B, Krause J, Wedekind D, Broocks A, Hajak G, Rüther E: Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with borderline personality disorder and healthy controls. Psychiatry Res 2005; 134:169–179
82.
Johnson JG, Cohen P, Brown J, Smailes EM, Bernstein DP: Childhood maltreatment increases risk for personality disorders during early adulthood. Arch Gen Psychiatry 1999; 56:600–606
83.
Carlson EA, Egeland B, Sroufe LA: A prospective investigation of the development of borderline personality symptoms. Dev Psychopathol 2009; 21:1311–1334
84.
Chanen AM, Kaess M: Developmental pathways to borderline personality disorder. Curr Psychiatry Rep 2012; 14:45–53
85.
Agrawal HR, Gunderson J, Holmes BM, Lyons-Ruth K: Attachment studies with borderline patients: a review. Harv Rev Psychiatry 2004; 12:94–104
86.
Levy KN: The implications of attachment theory and research for understanding borderline personality disorder. Dev Psychopathol 2005; 17:959–986
87.
Choi-Kain LW, Fitzmaurice GM, Zanarini MC, Laverdière O, Gunderson JG: The relationship between self-reported attachment styles, interpersonal dysfunction, and borderline personality disorder. J Nerv Ment Dis 2009; 197:816–821
88.
White CN, Gunderson JG, Zanarini MC, Hudson JI: Family studies of borderline personality disorder: a review. Harv Rev Psychiatry 2003; 11:8–19
89.
Torgersen S, Lygren S, Øien PA, Skre I, Onstad S, Edvardsen J, Tambs K, Kringlen E: A twin study of personality disorders. Compr Psychiatry 2000; 41:416–425
90.
Livesley WJ, Jang KL, Jackson DN, Vernon PA: Genetic and environmental contributions to dimensions of personality disorder. Am J Psychiatry 1993; 150:1826–1831
91.
Jang KL, Livesley WJ, Vernon PA, Jackson DN: Heritability of personality disorder traits: a twin study. Acta Psychiatr Scand 1996; 94:438–444
92.
Distel MA, Willemsen G, Ligthart L, Derom CA, Martin NG, Neale MC, Trull TJ, Boomsma DI: Genetic covariance structure of the four main features of borderline personality disorder. J Pers Disord 2010; 24:427–444
93.
Collier DA, Stöber GA, Li T, Heils A, Catalano M, Di Bella D, Arranz MJ, Murray RM, Vallada HP, Bengel D, Müller CR, Roberts GW, Smeraldi E, Kirov G, Sham P, Lesch KP: A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry 1996; 1:453–460
94.
Coccaro EF: Neurotransmitter correlates of impulsive aggression in humans. Ann N Y Acad Sci 1996; 794:82–89
95.
Simeon D, Stanley B, Frances A, Mann JJ, Winchel R, Stanley M: Self-mutilation in personality disorders: psychological and biological correlates. Am J Psychiatry 1992; 149:221–226
96.
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301:386–389
97.
Kendler KS, Kuhn JW, Vittum J, Prescott CA, Riley B: The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch Gen Psychiatry 2005; 62:529–535
98.
Wagner S, Baskaya O, Lieb K, Dahmen N, Tadić A: The 5-HTTLPR polymorphism modulates the association of serious life events (SLE) and impulsivity in patients with Borderline Personality Disorder. J Psychiatr Res 2009; 43:1067–1072
99.
Distel MA, Middeldorp CM, Trull TJ, Derom CA, Willemsen G, Boomsma DI: Life events and borderline personality features: the influence of gene-environment interaction and gene-environment correlation. Psychol Med 2011; 41:849–860
100.
Verschoor E, Markus CR: Affective and neuroendocrine stress reactivity to an academic examination: influence of the 5-HTTLPR genotype and trait neuroticism. Biol Psychol 2011; 87:439–449
101.
Orr SP, Lasko NB, Macklin ML, Pineles SL, Chang Y, Pitman RK: Predicting post-trauma stress symptoms from pre-trauma psychophysiologic reactivity, personality traits and measures of psychopathology. Biol Mood Anxiety Disord 2012; 2:8
102.
Herpertz SC, Dietrich TM, Wenning B, Krings T, Erberich SG, Willmes K, Thron A, Sass H: Evidence of abnormal amygdala functioning in borderline personality disorder: a functional MRI study. Biol Psychiatry 2001; 50:292–298
103.
Donegan NH, Sanislow CA, Blumberg HP, Fulbright RK, Lacadie C, Skudlarski P, Gore JC, Olson IR, McGlashan TH, Wexler BE: Amygdala hyperreactivity in borderline personality disorder: implications for emotional dysregulation. Biol Psychiatry 2003; 54:1284–1293
104.
Minzenberg MJ, Fan J, New AS, Tang CY, Siever LJ: Fronto-limbic dysfunction in response to facial emotion in borderline personality disorder: an event-related fMRI study. Psychiatry Res 2007; 155:231–243
105.
Ruocco AC, Medaglia JD, Ayaz H, Chute DL: Abnormal prefrontal cortical response during affective processing in borderline personality disorder. Psychiatry Res 2010; 182:117–122
106.
Silbersweig D, Clarkin JF, Goldstein M, Kernberg OF, Tuescher O, Levy KN, Brendel G, Pan H, Beutel M, Pavony MT, Epstein J, Lenzenweger MF, Thomas KM, Posner MI, Stern E: Failure of frontolimbic inhibitory function in the context of negative emotion in borderline personality disorder. Am J Psychiatry 2007; 164:1832–1841
107.
Ruocco AC, Amirthavasagam S, Choi-Kain LW, McMain SF: Neural correlates of negative emotionality in borderline personality disorder: an activation-likelihood-estimation meta-analysis. Biol Psychiatry 2013; 73:153–160
108.
Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH: Deep brain stimulation for treatment-resistant depression. Neuron 2005; 45:651–660
109.
King-Casas B, Sharp C, Lomax-Bream L, Lohrenz T, Fonagy P, Montague PR: The rupture and repair of cooperation in borderline personality disorder. Science 2008; 321:806–810
110.
LeGris J, van Reekum R: The neuropsychological correlates of borderline personality disorder and suicidal behaviour. Can J Psychiatry 2006; 51:131–142
111.
Fertuck EA, Lenzenweger MF, Clarkin JF, Hoermann S, Stanley B: Executive neurocognition, memory systems, and borderline personality disorder. Clin Psychol Rev 2006; 26:346–375
112.
Berlin HA, Rolls ET, Iversen SD: Borderline personality disorder, impulsivity, and the orbitofrontal cortex. Am J Psychiatry 2005; 162:2360–2373
113.
Zimmerman DJ, Choi-Kain LW: The hypothalamic-pituitary-adrenal axis in borderline personality disorder: a review. Harv Rev Psychiatry 2009; 17:167–183
114.
Stanley B, Siever LJ: The interpersonal dimension of borderline personality disorder: toward a neuropeptide model. Am J Psychiatry 2010; 167:24–39
115.
Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC: Oxytocin improves “mind-reading” in humans. Biol Psychiatry 2007; 61:731–733
116.
Bartz J, Simeon D, Hamilton H, Kim S, Crystal S, Braun A, Vicens V, Hollander E: Oxytocin can hinder trust and cooperation in borderline personality disorder. Soc Cogn Affect Neurosci 2011; 6:556–563
117.
First MB, Gibbon M, Spitzer RL, William JBW: Structured clinical interview for DSM-IV Axis I disorders – Patient version (SCID-I/P). New York, Biometrics Research Department, New York State Psychiatric Institute, 1996
118.
Loranger AW, Junca A, Sartorius N (ed): Assessment and diagnosis of personality disorders. The ICD-10 International Personality Disorder Examination. Cambridge, England, Cambridge Univ Press, 1997
119.
Pfohl B, Coryell W, Zimmerman M, Stangl D: Prognostic validity of self-report and interview measures of personality disorder in depressed inpatients. J Clin Psychiatry 1987; 48:468–472
120.
Zanarini MC, Frankenburg FR, Sickel AE, Yong L: The Diagnostic Interview for DSM-IV Personality Disorders (DIPD-IV). Belmont, MA, McLean Hospital, 1996
121.
Zimmerman M: A critique of the proposed prototype rating system for personality disorders in DSM-5. J Pers Disord 2011; 25:206–221
122.
Shedler J, Westen D: Refining personality disorder diagnosis: integrating science and practice. Am J Psychiatry 2004; 161:1350–1365
123.
Akiskal HS: Borderline: an adjective in search of a noun, in Handbook of Borderline Disorders. Edited by, Silver D, Rosenbluth M, et al. Madison, CT, International Universities Press, Inc, 1992, pp 155–177
124.
Stone M: Contemporary shift of the borderline concept from a sub-schizophrenic disorder to a subaffective disorder. Psychiatr Clin North Am 1979; 2:577–594
125.
Feurino L, Silk KR: State of the art in the pharmacologic treatment of borderline personality disorder. Curr Psychiatry Rep 2011; 13:69–75
126.
Ingenhoven T, Lafay P, Rinne T, Passchier J, Duivenvoorden H: Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry 2010; 71:14–25
127.
Paris J, Gunderson JG, Weinberg I: The interface between borderline personality disorder and bipolar spectrum disorders. Compr Psychiatry 2007; 48:145–154
128.
Zimmerman M, Ruggero CJ, Chelminski I, Young D: Psychiatric diagnoses in patients previously overdiagnosed with bipolar disorder. J Clin Psychiatry 2010; 71:26–31
129.
Hadjipavlou G, Mok H, Yatham LN: Pharmacotherapy of bipolar II disorder: a critical review of current evidence. Bipolar Disord 2004; 6:14–25
130.
Shelton MD, Calabrese JR: Current concepts in rapid cycling bipolar disorder. Curr Psychiatry Rep 2000; 2:310–315
131.
Waldinger RJ, Gunderson JG: Completed psychotherapies with borderline patients. Am J Psychother 1984; 38:190–202
132.
Bateman A, Fonagy P: 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. Am J Psychiatry 2008; 165:631–638
133.
Doering S, Hörz S, Rentrop M, Fischer-Kern M, Schuster P, Benecke C, Buchheim A, Martius P, Buchheim P: Transference-focused psychotherapy v. treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. Br J Psychiatry 2010; 196:389–395
134.
Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, Korslund KE, Tutek DA, Reynolds SK, Lindenboim N: Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 2006; 63:757–766
135.
McMain SF, Guimond T, Streiner DL, Cardish RJ, Links PS: Dialectical behavior therapy compared with general psychiatric management for borderline personality disorder: clinical outcomes and functioning over a 2-year follow-up. Am J Psychiatry 2012; 169:650–661
136.
Jørgensen CR, Freund C, Bøye R, Jordet H, Andersen D, Kjølbye M: Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. Acta Psychiatr Scand (Epub ahead of print: Aug 17, 2012;
137.
Bateman AW: Treating borderline personality disorder in clinical practice. Am J Psychiatry 2012; 169:560–563
138.
de Groot ER, Verheul R, Trijsburg RW: An integrative perspective on psychotherapeutic treatments for borderline personality disorder. J Pers Disord 2008; 22:332–352
139.
Gabbard GO: Do all roads lead to Rome? New findings on borderline personality disorder. Am J Psychiatry 2007; 164:853–855
140.
Livesely WJ: Handbook of Personality Disorders: Theory, Research, and Treatment. New York, Wiley, 2001
141.
Paris JL: Treatment of Borderline Personality Disorder: A Guide to Evidence-Based Practice. New York, The Guilford Press, 2008
142.
Weinberg I, Ronningstam E, Goldblatt MJ, Schechter M, Maltsberger JT: Common factors in empirically supported treatments of borderline personality disorder. Curr Psychiatry Rep 2011; 13:60–68
143.
McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, Streiner DL: A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. Am J Psychiatry 2009; 166:1365–1374
144.
Bateman A, Fonagy P: Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Am J Psychiatry 2009; 166:1355–1364
145.
Clarkin JF, Levy KN, Lenzenweger MF, Kernberg OF: Evaluating three treatments for borderline personality disorder: a multiwave study. Am J Psychiatry 2007; 164:922–928
146.
Gunderson JG, Stout RL, Shea MT, Keuroghlian A, Morey LC, Grilo CM, Sanislow C, Yen S, Zanarini MC, Markowitz JC, McGlashan TH, Skodol AE: Interactions of borderline personality disorder and mood disorders over ten years. Br J Psychiatry (under review)
147.
Stoffers JM, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K: Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev 2012; 8:CD005652
148.
Giesen-Bloo J, van Dyck R, Spinhoven P, van Tilburg W, Dirksen C, van Asselt T, Kremers I, Nadort M, Arntz A: Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Arch Gen Psychiatry 2006; 63:649–658
149.
Chanen AM, Jackson HJ, McCutcheon LK, Jovev M, Dudgeon P, Yuen HP, Germano D, Nistico H, McDougall E, Weinstein C, Clarkson V, McGorry PD: Early intervention for adolescents with borderline personality disorder using cognitive analytic therapy: randomised controlled trial. Br J Psychiatry 2008; 193:477–484
150.
Blum N, St John D, Pfohl B, Stuart S, McCormick B, Allen J, Arndt S, Black DW: Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. Am J Psychiatry 2008; 165:468–478
151.
Gunderson JG, Links P: Borderline Personality Disorder: A Clinical Guide, 2nd ed. Washington, DC, American Psychiatric Press, Inc., 2008
152.
Gunderson JG, Frank AF, Ronningstam EF, Wachter S, Lynch VJ, Wolf PJ: Early discontinuance of borderline patients from psychotherapy. J Nerv Ment Dis 1989; 177:38–42
153.
Goodman M, Patil U, Triebwasser J, Hoffman P, Weinstein ZA, New A: Parental burden associated with borderline personality disorder in female offspring. J Pers Disord 2011; 25:59–74
154.
Hoffman PD, Fruzzetti AE, Buteau E, Neiditch ER, Penney D, Bruce ML, Hellman F, Struening E: Family connections: a program for relatives of persons with borderline personality disorder. Fam Process 2005; 44:217–225
155.
Farrell JM, Shaw IA, Webber MA: A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. J Behav Ther Exp Psychiatry 2009; 40:317–328
156.
Gratz KL, Gunderson JG: Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behav Ther 2006; 37:25–35
157.
Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM: Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry 2010; 196:4–12
158.
Soloff PH: Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bull Menninger Clin 1998; 62:195–214
159.
Cowdry RW, Gardner DL: Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988; 45:111–119
160.
Orman JS, Keating GM: Spotlight on buprenorphine/naloxone in the treatment of opioid dependence. CNS Drugs 2009; 23:899–902
161.
Jørgensen CH, Pedersen B, Tønnesen H: The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res 2011; 35:1749–1758
162.
van den Bosch LM, Verheul R: Patients with addiction and personality disorder: Treatment outcomes and clinical implications. Curr Opin Psychiatry 2007; 20:67–71
163.
Mercer D, Douglass AB, Links PS: Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. J Pers Disord 2009; 23:156–174
164.
Bateman A, Fonagy P: Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry 1999; 156:1563–1569
165.
Stone MH, Stone DK, Hurt SW: Natural history of borderline patients treated by intensive hospitalization. Psychiatr Clin North Am 1987; 10:185–206
166.
Zanarini MC, Frankenburg FR, Hennen J, Silk KR: The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Am J Psychiatry 2003; 160:274–283
Information & Authors
Information
Published In
History
Published online: 1 April 2013
Published in print: Spring 2013
Authors
Funding Information
Author Information and CME Disclosure
John G. Gunderson, M.D., Professor in Psychiatry, Harvard Medical School and Director of the Borderline Personality Disorder Center, McLean Hospital, Belmont, MA
Igor Weinberg, Ph.D., Harvard Medical School, McLean Hospital, Belmont, MA
Lois Choi-Kain, M.D., Director, Gunderson Residence of McLean Hospital, Clinical Instructor of Psychiatry, Harvard Medical School
The authors report no competing interests.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
PDF/ePub
View PDF/ePubGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).